Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
TRUST-I
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
- NCT04395677 ↗
- Active, not recruiting
- Nuvation Bio Inc.
- Deep
We haven't built an HCP commentary report on TRUST-I (AB-106 in Non Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TRUST-I so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 24 | |
| YouTube | 8 | |
| Podcasts | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- AB-106
- Arms
- AB-106 （DS-6051b） · Experimental
- Enrollment
- 173
- Primary outcomes
- Best overall response (BOR) by IRC
- Sponsor
- Nuvation Bio Inc.
- Start
- Jul 7, 2020
- Primary completion
- Jun 7, 2024
- Results posted
- No
- Registry record
- NCT04395677 · updated Feb 6, 2026
Publications
linked from the registry- Li W, Zhang Y, Fan H, Yu Q, Ran F, Chen W, Zhou C. Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study. J Clin Oncol. 2026 Jun 20;44(18):1670-1675. doi: 10.1200/JCO-26-00434. Epub 2026 Apr 21. PubMed 42013573
- Perol M, Li W, Pennell NA, Liu G, Ohe Y, De Braud F, Nagasaka M, Felip E, Xiong A, Zhang Y, Fan H, Wang X, Li S, Lai RK, Ran F, Zhang X, Chen W, Bazhenova L, Zhou C. Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. J Clin Oncol. 2025 Jun;43(16):1920-1929. doi: 10.1200/JCO-25-00275. Epub 2025 Apr 3. PubMed 40179330
- Li W, Xiong A, Yang N, Fan H, Yu Q, Zhao Y, Wang Y, Meng X, Wu J, Wang Z, Liu Y, Wang X, Qin X, Lu K, Zhuang W, Ren Y, Zhang X, Yan B, Lovly CM, Zhou C. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study. J Clin Oncol. 2024 Aug 1;42(22):2660-2670. doi: 10.1200/JCO.24.00731. Epub 2024 Jun 1. PubMed 38822758